The Role of Thoracic Surgery in Small Cell Lung Cancer - A Large Longitudinal Analysis (2002-2015) Based on Real-World Data

被引:4
作者
Kauffmann-Guerrero, Diego [1 ,2 ,3 ,4 ]
Walter, Julia [1 ]
Kovacs, Julia [2 ,3 ,4 ,5 ]
Sellmer, Laura [1 ]
Hatz, Rudolf A. [2 ,3 ,4 ,5 ]
Behr, Juergen [1 ,2 ,3 ,4 ]
Schubert-Fritschle, Gabriele [6 ]
Tufman, Amanda [1 ,2 ,3 ,4 ]
Schneider, Christian P. [2 ,3 ,4 ,5 ]
机构
[1] Ludwig Maximilians Univ Munchen, Dept Med 5, Univ Hosp, Munich, Germany
[2] Comprehens Pneumol Ctr CPC, Munich, Germany
[3] German Ctr Lung Res DZL, Munich, Germany
[4] Univ Munich LMU, Munich, Germany
[5] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Thorac Surg, Munich, Germany
[6] Ludwig Maximilians Univ LMU, Inst Med Informat Proc Biometry & Epidemiol IBE, Munich Canc Registry MCR, Munich, Germany
关键词
Extensive disease; Limited disease; SCLC; Surgical management; Multimodal treatment; STAGE-I; SURGICAL RESECTION; CHEMOTHERAPY; TRIAL; CARCINOMA; LOBECTOMY; SURVIVAL;
D O I
10.1016/j.cllc.2022.01.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Most SCLC patients are diagnosed with extensive disease (ED) and the prognosis in this cohort remains poor. However, some patients are diagnosed with limited (LD) or very limited (VLD, T1-2, N0-1, M0) disease and previous data suggest that surgical resection might improve outcomes in these patients. Most of the existing evidence comes from small case series. For this reason, we investigated clinical features and surgical outcomes in a large cohort of resected SCLC patients. Patients and Methods: We used a large pseudomized dataset (n = 32432) provided by the Munich Cancer Registry to analyze all documented SCLC patients (n = 5043) between 2002 and 2015. We correlated patients??? characteristics as well as surgery modalities with survival data and describe trends in the role of surgery in SCLC over the time. Results: We analyzed 5043 SCLC patients. A total of 161 (3.2%) received either oncological (lobectomy, bilobectomy and pneumonectomy) or limited resection (segmentectomy and wedge resection). We found a significant trend suggesting that resections in SCLC patients become less common in all stages of disease, accompa-nied by an increased proportion of oncological resections. This suggests a more accurate preoperative staging. In VLD resection was significantly associated with longer survival compared to nonsurgical management (log-rank P = .013). Survival was better with oncological resection compared to atypical resection. Administration of adjuvant chemother-apy was associated with better outcome in all resected patients ( P = .01). Conclusion: VLD SCLC patients benefit from oncological resection. We recommend invasive staging in these patients to ensure VLD. Furthermore, adjuvant chemotherapy should be offered to all resected patients.
引用
收藏
页码:244 / 252
页数:9
相关论文
共 24 条
[1]  
[Anonymous], 2018, AWMF Registernummer AWMF-Register Nr. 088-001 AWMF Leitlinienregister
[2]  
[Anonymous], 2021, MUNICH CANC REGISTRY
[3]   Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base [J].
Combs, Susan E. ;
Hancock, Jacquelyn G. ;
Boffa, Daniel J. ;
Decker, Roy H. ;
Detterbeck, Frank C. ;
Kim, Anthony W. .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) :316-323
[4]   Reframing recalcitrance for small-cell lung cancer [J].
Blackhall, F. H. .
ANNALS OF ONCOLOGY, 2021, 32 (07) :829-830
[5]   Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB:: long-term results of a phase II trial [J].
Eberhardt, W ;
Stamatis, G ;
Stuschke, M ;
Wilke, H ;
Müller, MR ;
Kolks, S ;
Flasshove, M ;
Schütte, J ;
Stahl, M ;
Schlenger, L ;
Budach, V ;
Greschuchna, D ;
Stüben, G ;
Teschler, H ;
Sack, H ;
Seeber, S .
BRITISH JOURNAL OF CANCER, 1999, 81 (07) :1206-1212
[6]  
FOX W, 1973, LANCET, V2, P63
[7]   A pilot phase 2 study of surgical treatment after induction chemotherapy for resectable stage I to IIIA small cell lung cancer [J].
Fujimori, K ;
Yokoyama, A ;
Kurita, Y ;
Terashima, M .
CHEST, 1997, 111 (04) :1089-1093
[8]   SCLC-State of the Art and What Does the Future Have in Store? [J].
Kahnert, Kathrin ;
Kauffmann-Guerrero, Diego ;
Huber, Rudolf Maria .
CLINICAL LUNG CANCER, 2016, 17 (05) :325-333
[9]   NCCN Guidelines® Insights Small Cell Lung Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines [J].
Kalemkerian, Gregory P. ;
Loo, Billy W., Jr. ;
Akerley, Wallace ;
Attia, Albert ;
Bassetti, Michael ;
Boumber, Yanis ;
Decker, Roy ;
Dobelbower, M. Chris ;
Dowlati, Afshin ;
Downey, Robert J. ;
Florsheim, Charles ;
Ganti, Apar Kishor P. ;
Grecula, John C. ;
Gubens, Matthew A. ;
Hann, Christine L. ;
Hayman, James A. ;
Heist, Rebecca Suk ;
Koczywas, Marianna ;
Merritt, Robert E. ;
Mohindra, Nisha ;
Molina, Julian ;
Moran, Cesar A. ;
Morgensztern, Daniel ;
Pokharel, Saraswati ;
Portnoy, David C. ;
Rhodes, Deborah ;
Rusthoven, Chad ;
Santana-Davila, Rafael ;
Williams, Charles C., Jr. ;
Hoffmann, Karin G. ;
Hughes, Miranda .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (10) :1171-1182
[10]   SURGERY FOR CURE FOLLOWED BY CHEMOTHERAPY IN SMALL-CELL CARCINOMA OF THE LUNG [J].
KARRER, K ;
ULSPERGER, E .
ACTA ONCOLOGICA, 1995, 34 (07) :899-906